The effects of thiazolidinediones on metabolic complications and lipodystrophy in HIV-infected patients

PPAR Research

Volumn , Issue , 2009, Pages

  Sutinen, Jussi ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; EFAVIRENZ; FENOFIBRATE; GLITAZONE DERIVATIVE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METFORMIN; NELFINAVIR; NEVIRAPINE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; STAVUDINE; TENOFOVIR; TROGLITAZONE; ZIDOVUDINE;

BODY COMPOSITION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FATTY LIVER; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HIGH DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE;

EID: 60049097238     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2009/373524     Document Type: Review

References (107)

1. Jaggy C., von Overbeck J., Ledergerber B., Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population The Lancet 2003 362 9387 877 878
2. Pierson T., McArthur J., Siliciano R. F., Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy Annual Review of Immunology 2000 18 665 708
3. El-Sadr W. M., Lundgren J. D., Neaton J. D., CD4+ count-guided interruption of antiretroviral treatment The New England Journal of Medicine 2006 355 22 2283 2296
4. Friis-Møller N., Sabin C. A., Weber R., Combination antiretroviral therapy and the risk of myocardial infarction The New England Journal of Medicine 2003 349 21 1993 2003
5. Grinspoon S., Carr A., Cardiovascular risk and body-fat abnormalities in HIV-infected adults The New England Journal of Medicine 2005 352 1 48 62
6. Bacchetti P., Gripshover B., Grunfeld C., Fat distribution in men with HIV infection Journal of Acquired Immune Deficiency Syndromes 2005 40 2 121 131
7. Lebovitz H. E., Dole J. F., Patwardhan R., Rappaport E. B., Freed M. I., Rosiglitazone monotherapy is effective in patients with type 2 diabetes The Journal of Clinical Endocrinology & Metabolism 2001 86 1 280 288
8. Raskin P., Rendell M., Riddle M. C., Dole J. F., Freed M. I., Rosenstock J., A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes Diabetes Care 2001 24 7 1226 1232
9. Mayerson A. B., Hundal R. S., Dufour S., The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes Diabetes 2002 51 3 797 802
10. Arioglu E., Duncan-Morin J., Sebring N., Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes Annals of Internal Medicine 2000 133 4 263 274
11. Berger J., Moller D. E., The mechanisms of action of PPARs Annual Review of Medicine 2002 53 409 435
12. Yki-Järvinen H., Thiazolidinediones The New England Journal of Medicine 2004 351 11 1106 1118
13. Heikkinen S., Auwerx J., Argmann C. A., PPAR γ in human and mouse physiology Biochimica et Biophysica Acta 2007 1771 8 999 1013
14. Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. M., Kliewer S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ) The Journal of Biological Chemistry 1995 270 22 12953 12956
15. Spiegelman B. M., PPAR- γ: adipogenic regulator and thiazolidinedione receptor Diabetes 1998 47 4 507 514
16. Reus S., Arroyo E., Boix V., Portilla J., Lipodystrophy and hyperglycemia produced by protease inhibitors Anales de Medicina Interna 2000 17 3 123 126
17. Carr A., Samaras K., Thorisdottir A., Kaufmann G. R., Chisholm D. J., Cooper D. A., Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study The Lancet 1999 353 9170 2093 2099
18. Carr A., Cooper D. A., Adverse effects of antiretroviral therapy The Lancet 2000 356 9239 1423 1430
19. Schambelan M., Benson C. A., Carr A., Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel Journal of Acquired Immune Deficiency Syndromes 2002 31 3 257 275
20. Gallant J. E., Staszewski S., Pozniak A. L., Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial The Journal of the American Medical Association 2004 292 2 191 201
21. Podzamczer D., Ferrer E., Sanchez P., Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study Journal of Acquired Immune Deficiency Syndromes 2007 44 2 139 147
22. Saint-Marc T., Partisani M., Poizot-Martin I., A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy AIDS 1999 13 13 1659 1667
23. Savès M., Raffi F., Capeau J., Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy Clinical Infectious Diseases 2002 34 10 1396 1405
24. Mauss S., Corzillius M., Wolf E., Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment HIV Medicine 2002 3 1 49 55
25. van der Valk M., Gisolf E. H., Reiss P., Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection AIDS 2001 15 7 847 855
26. Dubé M. P., Komarow L., Mulligan K., Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides: dual X-ray absorptiometry results from A5005s, a substudy of adult clinical trials group 384 Journal of Acquired Immune Deficiency Syndromes 2007 45 5 508 514
27. Carr A., Workman C., Smith D. E., Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial The Journal of the American Medical Association 2002 288 2 207 215
28. Moyle G. J., Sabin C. A., Cartledge J., A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy AIDS 2006 20 16 2043 2050
29. Sutinen J., Interventions for managing antiretroviral therapy-associated lipoatrophy Current Opinion in Infectious Diseases 2005 18 1 25 33
30. Dubé M. P., Parker R. A., Tebas P., Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides AIDS 2005 19 16 1807 1818
31. Haubrich R. H., Riddler S., DiRienzo G., Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections (CROI '07) February 2007 Los Angeles, Calif, USA. Abstract 38
32. Hansen B. R., Haugaard S. B., Iversen J., Nielsen J. O., Andersen O., Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review Scandinavian Journal of Infectious Diseases 2004 36 4 244 253
33. Brinkman K., Smeitink J. A., Romijn J. A., Reiss P., Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy The Lancet 1999 354 9184 1112 1115
34. Pinti M., Salomoni P., Cossarizza A., Anti-HIV drugs and the mitochondria Biochimica et Biophysica Acta 2006 1757 5-6 700 707
35. Caron M., Auclair M., Lagathu C., The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro AIDS 2004 18 16 2127 2136
36. Shikuma C. M., Hu N., Milne C., Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy AIDS 2001 15 14 1801 1809
37. Walker U. A., Bickel M., Lütke Volksbeck S. I., Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients Journal of Acquired Immune Deficiency Syndromes 2002 29 2 117 121
38. Nolan D., Hammond E., Martin A., Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy AIDS 2003 17 9 1329 1338
39. Hammond E., Nolan D., James I., Metcalf C., Mallal S., Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy AIDS 2004 18 5 815 817
40. Mallon P. W. G., Unemori P., Sedwell R., In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA The Journal of Infectious Diseases 2005 191 10 1686 1696
41. Bastard J.-P., Caron M., Vidal H., Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance The Lancet 2002 359 9311 1026 1031
42. Kannisto K., Sutinen J., Korsheninnikova E., Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy AIDS 2003 17 12 1753 1762
43. Jan V., Cervera P., Maachi M., Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients Antiviral Therapy 2004 9 4 555 564
44. Lihn A. S., Richelsen B., Pedersen S. B., Increased expression of TNF- α, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels American Journal of Physiology 2003 285 5 E1072 E1080
45. Sutinen J., Korsheninnikova E., Funahashi T., Matsuzawa Y., Nyman T., Yki-Järvinen H., Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy The Journal of Clinical Endocrinology & Metabolism 2003 88 4 1907 1910
46. Mynarcik D. C., Combs T., McNurlan M. A., Scherer P. E., Komaroff E., Gelato M. C., Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution Journal of Acquired Immune Deficiency Syndromes 2002 31 5 514 520
47. Addy C. L., Gavrila A., Tsiodras S., Brodovicz K., Karchmer A. W., Mantzoros C. S., Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy The Journal of Clinical Endocrinology & Metabolism 2003 88 2 627 636
48. Sutinen J., Häkkinen A.-M., Westerbacka J., Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy AIDS 2002 16 16 2183 2193
49. Estrada V., Serrano-Ríos M., Martínez Larrad M. T., Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy Journal of Acquired Immune Deficiency Syndromes 2002 29 1 32 40
50. Gan S. K., Samaras K., Thompson C. H., Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy Diabetes 2002 51 11 3163 3169
51. Christeff N., Melchior J.-C., de Truchis P., Perronne C., Nunez E. A., Gougeon M.-L., Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations AIDS 1999 13 16 2251 2260
52. Kosmiski L., Kuritzkes D., Lichtenstein K., Eckel R., Adipocyte-derived hormone levels in HIV lipodystrophy Antiviral Therapy 2003 8 1 9 15
53. Domingo P., Matias-Guiu X., Pujol R. M., Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy AIDS 1999 13 16 2261 2267
54. Gelato M. C., Mynarcik D. C., Quick J. L., Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study Journal of Acquired Immune Deficiency Syndromes 2002 31 2 163 170
55. Sutinen J., Häkkinen A.-M., Westerbacka J., Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study Antiviral Therapy 2003 8 3 199 207
56. Carr A., Workman C., Carey D., No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial The Lancet 2004 363 9407 429 438
57. Hadigan C., Yawetz S., Thomas A., Havers F., Sax P. E., Grinspoon S., Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial Annals of Internal Medicine 2004 140 10 786 794
58. van Wijk J. P. H., de Koning E. J. P., Cabezas M. C., Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial Annals of Internal Medicine 2005 143 5 337 346
59. Feldt T., Oette M., Kroidl A., Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome Infection 2006 34 2 55 61
60. Mulligan K., Yang Y., Wininger D. A., Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio AIDS 2007 21 1 47 57
61. Haider D. G., Schindler K., Mittermayer F., Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients Clinical Pharmacology & Therapeutics 2007 81 4 580 585
62. Cavalcanti R. B., Raboud J., Shen S., Kain K. C., Cheung A., Walmsley S., A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy The Journal of Infectious Diseases 2007 195 12 1754 1761
63. Silič A., Janež A., Tomažič J., Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial Croatian Medical Journal 2007 48 6 791 799
64. Calmy A., Hirschel B., Karsegaard L., A pilot study for the use of pioglitazone in the treatment of highly active antiretroviral therapy lipodystrophy syndromes Antiviral Therapy 2001 6 supplement 4 32
65. Gavrila A., Hsu W., Tsiodras S., Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial Clinical Infectious Diseases 2005 40 5 745 749
66. Slama L., Lanoy E., Valantin M.-A., Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113) Antiviral Therapy 2008 13 1 67 76
67. Walli R., Michl G. M., Mühlbayer D., Brinkmann L., Goebel F. D., Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus Research in Experimental Medicine 2000 199 5 253 262
68. Miyazaki Y., Glass L., Triplitt C., Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients Diabetologia 2001 44 12 2210 2219
69. Carey D. G., Cowin G. J., Galloway G. J., Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients Obesity Research 2002 10 10 1008 1015
70. Phillips L. S., Grunberger G., Miller E., Patwardhan R., Rappaport E. B., Salzman A., Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes Diabetes Care 2001 24 2 308 315
71. Shadid S., Stehouwer C. D. A., Jensen M. D., Diet/exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers The Journal of Clinical Endocrinology & Metabolism 2006 91 9 3418 3425
72. Balas B., Belfort R., Harrison S. A., Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis Journal of Hepatology 2007 47 4 565 570
73. Mafong D. D., Lee G. A., Yu S., Tien P., Mauro T., Grunfeld C., Development of multiple lipomas during treatment with rosiglitazone in a patient with HIV-associated lipoatropny AIDS 2004 18 12 1742 1744
74. Hadigan C., Mazza S., Crum D., Grinspoon S., Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients AIDS 2007 21 18 2543 2546
75. Normén L., Frohlich J., Montaner J., Harris M., Elliott T., Bondy G., Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol Diabetes Care 2004 27 9 2241 2242
76. Sutinen J., Kannisto K., Korsheninnikova E., Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy American Journal of Physiology 2004 286 6 E941 E949
77. Kovacic J. C., Martin A., Carey D., Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy Antiviral Therapy 2005 10 1 135 143
78. Kamin D., Hadigan C., Lehrke M., Mazza S., Lazar M. A., Grinspoon S., Resistin levels in human immunodeficiency virus-infected patients with lipoatrophy decrease in response to rosiglitazone The Journal of Clinical Endocrinology & Metabolism 2005 90 6 3423 3426
79. Yki-Järvinen H., Sutinen J., Silveira A., Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 4 688 694
80. Coll B., van Wijk J. P. H., Parra S., Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy European Journal of Pharmacology 2006 544 1-3 104 110
81. Mallon P., Sedwell R., Rogers G., The effect of rosiglitazone on PPAR- γ expression in human adipose tissue is limited by continued exposure to thymidine NRTI Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections February 2005 Boston, Mass, USA
82. Tiikkainen M., Häkkinen A.-M., Korsheninnikova E., Nyman T., Mäkimattila S., Yki-Järvinen H., Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes Diabetes 2004 53 8 2169 2176
83. Hammarstedt A., Pihlajamäki J., Graham T. E., High circulating levels of RBP4 and mRNA levels of aP2, PGC-1 α and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naive type 2 diabetic subjects Journal of Internal Medicine 2008 263 4 440 449
84. Tan G. D., Fielding B. A., Currie J. M., The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes Diabetologia 2005 48 1 83 95
85. Staels B., PPARgamma and atherosclerosis Current Medical Research and Opinion 2005 21 supplement 1 S13 S20
86. Nissen S. E., Wolski K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes The New England Journal of Medicine 2007 356 24 2457 2471
87. Singh S., Loke Y. K., Furberg C. D., Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis Journal of the American Medical Association 2007 298 10 1189 1195
88. Lincoff A. M., Wolski K., Nicholls S. J., Nissen S. E., Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials Journal of the American Medical Association 2007 298 10 1180 1188
89. Doggrell S. A., Clinical trials with thiazolidinediones in subjects with type 2 diabetes - is pioglitazone any different from rosiglitazone? Expert Opinion on Pharmacotherapy 2008 9 3 405 420
90. Berria R., Glass L., Mahankali A., Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in type II diabetes mellitus Clinical Pharmacology & Therapeutics 2007 82 3 275 281
91. Koka P. S., Reddy S. T., Cytopenias in HIV infection: mechanisms and alleviation of hematopoietic inhibition Current HIV Research 2004 2 3 275 282
92. Gale E. A. M., Lessons from the glitazones: a story of drug development The Lancet 2001 357 9271 1870 1875
93. Murphy C. E., Rodgers P. T., Effects of thiazolidinediones on bone loss and fracture Annals of Pharmacotherapy 2007 41 12 2014 2018
94. Brown T. T., Qaqish R. B., Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review AIDS 2006 20 17 2165 2174
95. Barry M., Mulcahy F., Merry C., Gibbons S., Back D., Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection Clinical Pharmacokinetics 1999 36 4 289 304
96. Oette M., Kurowski M., Feldt T., Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients Journal of Antimicrobial Chemotherapy 2005 56 2 416 419
97. Skolnik P. R., Rabbi M. F., Mathys J.-M., Greenberg A. S., Stimulation of peroxisome proliferator-activated receptors α and γ blocks HIV-1 replication and TNF α production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects Journal of Acquired Immune Deficiency Syndromes 2002 31 1 1 10
98. Hayes M. M., Lane B. R., King S. R., Markovitz D. M., Coffey M. J., Peroxisome proliferator-activated receptor γ agonists inhibit HIV-1 replication in macrophages by transcriptional and post-transcriptional effects The Journal of Biological Chemistry 2002 277 19 16913 16919
99. Boyd M. A., Carr A., Ruxrungtham K., Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz The Journal of Infectious Diseases 2006 194 5 642 650
100. Sutinen J., Walker U. A., Sevastianova K., Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial Antiviral Therapy 2007 12 1 97 105
101. Mallon P. W. G., Miller J., Kovacic J. C., Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men-a randomized, placebo-controlled study AIDS 2006 20 7 1003 1010
102. Clumeck N., Pozniak A., Raffi F., European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults HIV Medicine 2008 9 2 65 71
103. Hadigan C., Corcoran C., Basgoz N., Davis B., Sax P., Grinspoon S., Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial The Journal of the American Medical Association 2000 284 4 472 477
104. Gaslightwala I., Bini E. J., Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection Journal of Hepatology 2006 44 6 1026 1032
105. Castera L., Loko M. A., Le Bail B., Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype Alimentary Pharmacology & Therapeutics 2007 26 11-12 1489 1498
106. Monto A., Dove L. M., Bostrom A., Kakar S., Tien P. C., Wright T. L., Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection Hepatology 2005 42 2 310 316
107. Belfort R., Harrison S. A., Brown K., A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis The New England Journal of Medicine 2006 355 22 2297 2307